Relmada Therapeutics 株価情報 (NASDAQ: RLMD)

最新ニュース Relmada Therapeutics (NASDAQ:RLMD) 株価情報

Relmada Therapeutics

Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.

Relmada Therapeutics, Inc. - Common Stock

Relmada Therapeutics Inc

Citigroup analyst Thomas Palmer maintains JM Smucker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SJM#NYSE">SJM</a>) with a Buy and lowers the price target from $129 to $128.

News

Price Target

Analyst Ratings

Citigroup Maintains Buy on JM Smucker, Lowers Price Target to $128

Citigroup analyst Kyle Menges maintains Deere (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>) with a Neutral and raises the price target from $450 to $550.

Citigroup Maintains Neutral on Deere, Raises Price Target to $550

<a href="https://www.youtube.com/watch?v=SVkv-AtRBDY" title="https://www.youtube.com/watch?v=SVkv-AtRBDY">https://www.youtube.com/watch?v=SVkv-AtRBDY</a>

Events

MSFT

Live At Microsoft Build; Microsoft Introduces Github Copilot Coding Agent; Says Microsoft Will Host xAI Grok, Mistral And Black Forest Lab AI Models From Azure Data Centers

Palo Alto Networks Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) is scheduled to report its fiscal third-quarter results on Tuesday, May 20.
The announcement will come amid an <a href="https://www.benzinga.com/earnings">exciting earnings season</a>. Here are some key analyst previews.
<h1 class="wp-block-heading">Cantor Fitzgerald On Palo Alto Networks</h1>
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58d11d3db85e93000188d7b9/jonathan-ruykhaver">Analyst Jonathan Ruykhaver</a> reiterated an Overweight rating and price target of $223.
Checks indicate that Palo Alto Networks will report mixed result for the fiscal third quarter, Ruykhaver said in a note. The consensus estimates for NNARR (net new annual recurring revenue) of around $260 million implies a 6% year-on-year decline, "which we view as conservative despite the mixed checks," he added.
The analyst expects Palo Alto Networks to report revenues at $2.285 and earnings of 79 cents per share, higher than consensus of $2.279 billion and 77 cents per share, respectively. "Partner feedback on large deal momentum is largely consistent with last quarter, which should support at least an in-line 4Q25 guide for RPO, which currently stands at 19%-20%," he further wrote.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
<h1 class="wp-block-heading">Roth Capital Partners On Palo Alto Networks</h1>
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58ad8d48b85e930001f97170/robert-ohmes">Analyst</a><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58ad8d48b85e930001f97170/robert-ohmes"> Taz Koujalgi</a> maintained a Neutral rating and price target of $210.
Palo Alto Networks' revenues could fall short of the high end of the guidance range and management may not raise full-year NGS ARR (next-generation security annual recurring revenue) and RPO (remaining performance obligation) guidance, Koujalgi said.
"PANW's feedback improved from the end of March but was consistent with the end of January," the analyst wrote. Although feedback indicates large deals during the quarter, some of the pipeline deals that were expected to close in the fiscal fourth quarter could be pushed out to fiscal 2026, he further stated.
<h1 class="wp-block-heading">DA Davidson On Palo Alto Networks</h1>
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/61152e71b4035700018afbc0/rudy-kessinger">Analyst Rudy Kessinger</a> reaffirmed a Buy rating and price target of $225.
Palo Alto Networks is likely to report "in-line to modestly ahead" quarterly results and reiterate its full-year guidance, Kessinger said. Although checks indicate weaker third-quarter sales, the company had "the strongest feedback out of all vendors," which are likely to report significant sequential declines, he added.
Although Palo Alto Networks may report a strong quarter, the upside could be less than in previous quarters and fail to drive the share price in the near term, the analyst stated. "Total RPO growth &amp; CRPO growth could actually result in a negative near-term reaction in our view," he further wrote.
PANW Price Action: Shares of Palo Alto Networks had declined slightly by 0.021% to $192.94 at the time of publication on Monday.
Read More: • <a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45262278/under-armour-faces-tough-road-ahead-says-analyst">T-Mobile, Palo Alto Partner To Enhance 5G Cybersecurity For US Businesses</a>

Analyst Color

Previews

Reiteration

PANW

Palo Alto Networks Q3 Preview: Modest Upside Likely, Market Reaction May Remain Subdued, Analysts Say

Citigroup analyst Lydia Ling maintains RLX Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RLX#NYSE">RLX</a>) with a Neutral and lowers the price target from $2.5 to $2.25.

Citigroup Maintains Neutral on RLX Technology, Lowers Price Target to $2.25

Maxim Group analyst Tate Sullivan maintains Beam Glb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEEM#NASDAQ">BEEM</a>) with a Buy and lowers the price target from $5 to $4.

BEEM

Maxim Group Maintains Buy on Beam Glb, Lowers Price Target to $4

Freightos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRGO#NASDAQ">CRGO</a>) will release its quarterly earnings report on Tuesday, 2025-05-20. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Freightos to report an earnings per share (EPS) of $-0.09.
Investors in Freightos are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Earnings History Snapshot</h3>
The company's EPS beat by $0.02 in the last quarter, leading to a 3.71% drop in the share price on the following day.
Here's a look at Freightos's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.09</td>
<td>-0.16</td>
<td></td>
<td>-0.12</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.07</td>
<td>-0.04</td>
<td>-0.05</td>
<td>-0.06</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-4.0%</td>
<td>0.0%</td>
<td>1.0%</td>
<td>-5.0%</td>
</tr>
</tbody>
</table>

<h3>Performance of Freightos Shares</h3>
Shares of Freightos were trading at $2.27 as of May 16. Over the last 52-week period, shares are down 3.56%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/CRGO/earnings">To track all earnings releases for Freightos visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

CRGO

Freightos's Earnings Outlook

Hershey's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSY#NYSE">HSY</a>) short percent of float has risen 5.34% since its last report. The company recently reported that it has 8.22 million shares sold short, which is 6.51% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.57 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Hershey Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747670433_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Hershey has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Hershey's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Hershey's peer group average for short interest as a percentage of float is 6.16%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Is the Market Bullish or Bearish on Hershey?

Macro Economic Events

Global

Economics

Watching JP Morgan; CEO Jamie Dimon Reportedly Says There Is An Extraordinary Amount Of Complacency Over U.S. Debt, Trade Policies; Banking Supervisors Went "Far Beyond What Was Reasonable"; Industry Will Have Opportunity To Dispute Supervisory Activity

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

$BTC

Watching JP Morgan; CEO Jamie Dimon Reportedly Says Blockchain Doesn't Matter As Much As You Think; We Are Not Looking To Custody Crypto; Nothing Has Changed On Succession; We Should Always Be Thinking About Acquisitions; Geopolitical Risk Is Very, Very High; We Have Lost Some Business With Global Clients Choosing Local Lenders Since Tariffs

Cavco Indus's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVCO#NYSE">CVCO</a>) short percent of float has risen 14.12% since its last report. The company recently reported that it has 194 thousand shares sold short, which is 2.91% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.64 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Cavco Indus Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747670428_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Cavco Indus has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Cavco Indus's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Cavco Indus's peer group average for short interest as a percentage of float is 7.80%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

CVCO

Is Cavco Indus Gaining or Losing Market Support?

Palomar Hldgs's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLMR#NYSE">PLMR</a>) short percent of float has fallen 7.75% since its last report. The company recently reported that it has 579 thousand shares sold short, which is 2.62% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.02 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Palomar Hldgs Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747670423_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Palomar Hldgs has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Palomar Hldgs's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Palomar Hldgs's peer group average for short interest as a percentage of float is 2.44%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

PLMR

Peering Into Palomar Hldgs's Recent Short Interest

In the current market session, Zoetis Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) share price is at $161.01, after a 1.25% decrease. Over the past month, the stock increased by 8.79%, but over the past year, it actually fell by 5.56%. With good short-term performance like this, and questionable long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio.

<img src="https://www.benzinga.com/files/images/story/2025/1747670419_0.png" alt="Past Year Chart" />

<h3>How Does Zoetis P/E Compare to Other Companies?</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Zoetis has a better P/E ratio of 29.27 than the aggregate P/E ratio of 24.46 of the Pharmaceuticals industry. Ideally, one might believe that Zoetis Inc. might perform better in the future than it's industry group, but it's probable that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1747670420_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

A Look Into Zoetis Inc's Price Over Earnings

Building wealth is a long-term journey. You have to diligently save and invest money over many years. However, modern banking tools make it easier to build a big nest egg on autopilot. You don't have to make each deposit into your stock portfolio or spend too much time monitoring the market.
Financial guru Vincent Chan lays out a path where people in their 20s can <a href="https://www.tiktok.com/@vincentchanco/video/7504269967353777441?lang=en">become millionaires by the time they retire</a>. However, since the strategy is on autopilot, it gives you time to focus on other things.
"You can pretty much forget about it until you're 60," Chan states.
Don't Miss:
<ul class="wp-block-list">
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">Invest before it's too late.</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.30/share!</a></li>
</ul>
This claim only applies once you have the autopilot strategy in place. Here's how you can start building wealth without having to check your bank account every day.
<h2 class="wp-block-heading">Open A Roth IRA</h2>
Chan starts the video by recommending that his viewers open a Roth IRA at an established brokerage firm like Fidelity, Vanguard, or Schwab. Roth IRAs allow you to grow money tax-free, so you won't have to worry about capital gains when you retire.&nbsp;
These top brokerages offer simple user experiences that allow you to find what you need. They also have various financial services beyond Roth IRAs that can help you build wealth.
It's pretty easy to open a Roth IRA, and you don't have to be employed to get started. It works great for freelancers or individuals who want to contribute additional funds to a new retirement plan. Contributing to a Roth IRA does not affect your ability to contribute to an employer-sponsored retirement plan.
Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — <a href="https://www.benzinga.com/money/boxabl-scaling-fast-from-spacex-orders-to-600-homes-built-this-60k-foldable-home-may-be-the-future-of-housing">this is your last chance to become an investor for $0.80 per share.</a>
<h2 class="wp-block-heading">Transfer $7.20 To Your Roth IRA Every Day</h2>
The next step in this autopilot plan is to transfer $7.20 to your Roth IRA every day. Keep in mind that this money will be taxed, but you won't pay taxes when you withdraw it. Contributing $7.20 per day to a Roth IRA results in $2,628 per year for years with 365 days.&nbsp;
However, you can contribute much more than $2,628 per year. The IRS currently limits taxpayers to an annual $7,000 contribution to a Roth IRA. However, anyone who is 50 years or older can contribute an additional $1,000 per year to their Roth IRA.&nbsp;
If you want to contribute $7,000 per year, you will have to transfer $19.17 per day. People who qualify for an $8,000 annual contribution should invest $21.91 per day.&nbsp;
The IRS periodically raises the maximum contribution limits, so it's good to stay updated and adjust your daily transfer accordingly. If daily transfers are too stressful, you can also opt for weekly or monthly transfers.&nbsp;
See Also: Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>.&nbsp;
<h2 class="wp-block-heading">Automatically Invest In An S&amp;P 500 Fund</h2>
Chan encourages his audience to keep it simple and invest in an S&amp;P 500 fund. He mentions the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and the Vanguard S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOO#NYSE">VOO</a>) as potential choices. Notably, VOO only has a 0.03% expense ratio while SPY has a 0.09% expense ratio. VOO is technically cheaper to own, and both funds deliver nearly identical returns.
Chan mentions that the S&amp;P 500 usually goes up by 7% to 10% per year. The S&amp;P 500 automatically diversifies your money across the 500 largest profitable corporations. Companies are added or removed to the index based on their performance. It's a market-weighted index, so the tech giants will have more preference than companies with market caps just above $20 billion.
Read Next:
<ul class="wp-block-list">
<li>The team behind $6B+ in licensing deals is now building the next billion-dollar IP empire — <a href="https://www.benzinga.com/money/elf-labs-ym?v=123">invest early at $2.25/share.</a></li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.30/share with a $1000 minimum.</a></li>
</ul>
Image: Shutterstock

Personal Finance

Vincent Chan Shares How People In Their 20s Can Build Wealth On Autopilot: 'You Can Pretty Much Forget About It Until You're 60'

While Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) trades near its all time high price, Abdul Rafay Gadit, co-founder of ZigChain, believes that the broader crypto market is <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45489390/crypto-traders-who-secured-a-dinner-with-donald-trump-walked-away-with-major-profits-says-">primed for a shift</a>.
What Happened: In an interview with Benzinga, Gadit argued that investors should prepare for a strong rotation into altcoins as macroeconomic pressures ease and interest rates begin to fall.
He also named decentralized finance and tokenization as the most undervalued sectors in crypto, citing their real-world utility and long-term growth potential.
"Eighty to ninety percent of tokens are down, but Bitcoin has skewed the entire market perception," Gadit said. "Once rate cuts begin and inflation stabilizes, money will flow to other assets as well." 
While he acknowledged the dominance of Bitcoin in attracting institutional capital, Gadit insisted that altcoins tied to productive use cases will be the next to gain traction.
Bullish On Tokenization And DeFi
Gadit is particularly optimistic about the future of tokenized real-world assets (RWAs). 
He believes that bringing traditionally illiquid assets such as real estate, private credit, and equities onto blockchain rails will drive the next wave of crypto adoption.
"The DeFi sector overall, especially tokenization, is pretty much undervalued right now," he said. "If a real use case of AI or tokenization can lower the operational costs of blockchain, it could be massively disruptive."
ZigChain is currently working with Zamanat, a Sharia-compliant RWA tokenization platform, to tokenize $2.5 billion worth of real estate in Dubai over the next three years. 
"Think of a $15 million family office that usually can&#8217;t access private credit deals with high entry minimums. Through tokenization, even those chunks can be broken down into $1,000 units and accessed globally," he said.
Retail Inclusion And Infrastructure Investment
While other platforms like Ondo Finance (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">ONDO</a>) focus on institutions, ZigChain is betting on retail adoption. 
Gadit emphasized that ZigChain is building an all-in-one infrastructure layer that enables tokenized assets, stablecoins, and DeFi products to co-exist seamlessly. 
"The end user should not even feel that they are working on a blockchain," he said.
Gadit also disclosed that ZigChain is investing in acquiring a fund tokenization license from the Dubai International Financial Centre (DIFC), viewing this as a key milestone in legitimizing tokenized asset offerings. 
"That license alone shows how serious we are. Most serious tokenization players won't even launch their own token for the next five years—they're focused on infrastructure," he noted.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45496435/strategy-adds-765-million-in-bitcoin-faces-lawsuit-over-btc-holdings">Strategy Adds $765 Million In Bitcoin, Faces Lawsuit Over BTC Holdings</a>
From Bitcoin To Altcoins: Institutional Appetite Matures
Despite ongoing regulatory shifts and geopolitical uncertainty, Gadit is confident that institutional interest in crypto is accelerating. 
"Every day in Dubai, I meet someone from a large family office or desk who's looking to enter crypto," he said. "It always starts with Bitcoin, but eventually they begin to explore other tokens and asset classes."
He added that this institutional behavior, especially after spot Bitcoin ETF approvals, has helped Bitcoin maintain its strength above $100,000. 
However, Gadit expects a shift: "Barring any black swan events, I think my thesis for the next 12 to 24 months is that the market will do well, and altcoins will catch up."
In terms of specific sectors, Gadit highlighted three areas with high long-term potential: Layer-1 blockchains with real use cases, exchange tokens, and tokenized assets. "DEX tokens like Uniswap and Radium will benefit as volumes shift to decentralized trading venues. 
Exchanges, whether Bitget or Binance, are just buy-and-hold bets for me," he added.
Crypto Investing Is Maturing
Gadit believes the market is becoming more disciplined in how it evaluates crypto projects. 
"Gone are the days when you could raise money on promises alone," he said. "Now, revenue and user adoption are the key metrics. Token price is no longer enough."
He noted that many high-profile protocols have underperformed due to inflated valuations and poorly designed tokenomics. "It's the fault of the cap table. When investors are already 10x up at launch, you're racing to the bottom."
Even with ongoing hype cycles, whether around AI or other narratives, Gadit believes real utility will win out. "We use AI internally to reduce costs and increase margin, but we don't shout about it. The projects that quietly solve real problems will be the ones that last."
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45490643/el-salvadors-bitcoin-holdings-show-357-million-in-unrealized-profit-as-bitcoin-closes-at-record-highs">El Salvador&#8217;s Bitcoin Holdings Show $357 Million In Unrealized Profit As Bitcoin Closes At Record Highs</a></li>
</ul>
Image: Shutterstock

$ONDO

Altcoin Rotation Is Coming, Expert Says: Will ETH, XRP, Dogecoin Benefit?

Morgan Stanley analyst Michael Phillips maintains RenaissanceRe Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNR#NYSE">RNR</a>) with a Overweight and raises the price target from $275 to $285.

Morgan Stanley Maintains Overweight on RenaissanceRe Holdings, Raises Price Target to $285

Maxim Group analyst Jason McCarthy maintains MetaVia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTVA#NASDAQ">MTVA</a>) with a Buy and lowers the price target from $6 to $3.

MTVA

Maxim Group Maintains Buy on MetaVia, Lowers Price Target to $3

<figure class="wp-block-image aligncenter size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="683" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19081653/Top-Image-1024x683.png" alt="" class="wp-image-13068" style="width:920px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19081653/Top-Image-1024x683.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19081653/Top-Image-300x200.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19081653/Top-Image-768x512.png 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19081653/Top-Image.png 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<h2 class="wp-block-heading">A Threat To The Diabetes Cash Cow</h2>
Years ago, in a conversation with an endocrinologist, I mentioned there was no incentive to cure diabetes, giving the money companies were making from managing it (with testing supplies, insulin, etc.). He replied that the incumbents had no incentive to cure it, but a startup company would. Now it looks like one has—at least in one patient. Sana Biotechnology, Inc.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANA#NASDAQ">SANA</a>) has developed a one-time treatment that could upend the entire diabetes industry.
<h2 class="wp-block-heading">How It Works</h2>
Type 1 diabetes occurs when the immune system destroys the pancreatic beta cells, which are responsible for producing insulin. While transplants of donor islets—clusters of cells that include beta cells—can restore insulin production, they require scarce donor tissue and lifelong immunosuppressive drugs, which carry serious risks. As a result, insulin remains the only practical treatment for nearly all Type 1 diabetics.&nbsp;Sana has successfully engineered donor-derived islets to evade immune rejection, enabling a Type 1 diabetic to produce his own insulin, without the need for immunosuppressive drugs.
This isn't just theory. In a clinical trial at Uppsala University in Sweden, Sana's genetically engineered pancreatic islets were injected into the forearm of a Type 1 diabetic. As the company noted in its annual report, this patient is now&nbsp;more than three months post-treatment, making his own insulin for the first time in 30 years—with no immunosuppressive therapy.
A recent presentation by Sana shows the results of this experiment so far. The C-peptide mentioned there is a biomarker of insulin production.
<figure class="wp-block-image aligncenter size-large"><img loading="lazy" decoding="async" width="1024" height="578" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19081738/Clinical-Results-1024x578.jpg" alt="" class="wp-image-13069" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19081738/Clinical-Results-1024x578.jpg 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19081738/Clinical-Results-300x169.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19081738/Clinical-Results-768x433.jpg 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19081738/Clinical-Results.jpg 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Slides from Sana's <a href="https://ir.sana.com/static-files/1f3a1d8c-24eb-4695-9380-747332ddae2a">May 2025 Corporate Presentation</a>.</figcaption></figure>
As the subsequent slide in the presentation shows, the patient was producing no insulin before the procedure, but has been producing insulin consistently since.
<figure class="wp-block-image aligncenter size-large"><img loading="lazy" decoding="async" width="1024" height="580" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19081849/C-Peptide-Slide-1024x580.jpg" alt="" class="wp-image-13070" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19081849/C-Peptide-Slide-1024x580.jpg 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19081849/C-Peptide-Slide-300x170.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19081849/C-Peptide-Slide-768x435.jpg 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19081849/C-Peptide-Slide.jpg 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<h2 class="wp-block-heading">The Plan For Mass Production</h2>
The islet cells used in that trial came from a cadaveric donor. Sana's goal is to scale this breakthrough using&nbsp;stem cell–derived islets—which contain insulin-producing beta cells—that can be manufactured in large quantities and delivered off the shelf. The result would be a&nbsp;one-time treatment&nbsp;that could eliminate the need for insulin, blood sugar monitoring, and other diabetes therapies.
<figure class="wp-block-image aligncenter size-large"><img loading="lazy" decoding="async" width="1024" height="575" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19081940/One-time-treatment-1024x575.jpg" alt="" class="wp-image-13071" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19081940/One-time-treatment-1024x575.jpg 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19081940/One-time-treatment-300x169.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19081940/One-time-treatment-768x431.jpg 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19081940/One-time-treatment.jpg 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Larger dose‑escalation cohorts under way, with 6‑ and 12‑month read‑outs expected over the next year.
<h3 class="wp-block-heading">The Potential Market Impact</h3>
If the current results hold up, Sana's therapy would convert Type‑1 diabetes from a&nbsp;chronic drug‑and‑device market&nbsp;into a&nbsp;one‑time cell‑therapy market—a seismic shift for incumbents.
<figure class="wp-block-image aligncenter size-full"><img loading="lazy" decoding="async" width="963" height="547" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19082028/Market-Impact.png" alt="" class="wp-image-13072" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19082028/Market-Impact.png 963w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19082028/Market-Impact-300x170.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19082028/Market-Impact-768x436.png 768w" sizes="(max-width: 963px) 100vw, 963px" /></figure>
As you can see above, diabetes therapies comprise 75% of Novo Nordisk A/S&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) sales and 43% of Ely Lilly and Company&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>). For DexCom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) and Insulet Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>), diabetes is pretty much their entire businesses.
<h2 class="wp-block-heading">The Timeline That Matters</h2>
Some potential milestones to keep in mind for Sana headlines that could impact the diabetes therapy industry.
<figure class="wp-block-image aligncenter size-large"><img loading="lazy" decoding="async" width="1024" height="527" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19082137/Timeline-1024x527.png" alt="" class="wp-image-13073" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19082137/Timeline-1024x527.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19082137/Timeline-300x154.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19082137/Timeline-768x395.png 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19082137/Timeline.png 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<h2 class="wp-block-heading">The Bottom Line</h2>
Sana has not&nbsp;cured&nbsp;diabetes yet—but a&nbsp;&gt; 3‑month insulin‑free human case without immunosuppression&nbsp;is more evidence than the market usually prices into chronically‑treated franchises. Shareholders of the incumbent companies mentioned above ought to consider hedging. The Portfolio Armor iPhone app can help you find the least expensive hedge that fits your risk tolerance and time frame. You can download it by aiming your iPhone camera at the QR code below (or by&nbsp;<a href="https://apps.apple.com/us/app/portfolio-armor/id394951144">tapping here</a>, if you are reading this on your iPhone).
<figure class="wp-block-image size-large"><a href="https://apps.apple.com/us/app/portfolio-armor/id394951144"><img loading="lazy" decoding="async" width="1024" height="683" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19082314/PA-JPEG-5-1024x683.jpeg" alt="" class="wp-image-13074" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19082314/PA-JPEG-5-1024x683.jpeg 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19082314/PA-JPEG-5-300x200.jpeg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19082314/PA-JPEG-5-768x512.jpeg 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19082314/PA-JPEG-5.jpeg 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Enterprising investors might also consider adding a small position in SANA. There's asymmetric upside potential if follow‑up cohorts validate the initial results. My subscribers and I bought shares in the company earlier this year, and then LEAPS on it last week, now that the stock has options traded on it.
<figure class="wp-block-image aligncenter size-full"><a href="https://portfolioarmor.substack.com/p/trade-alert-pharma-panic"><img loading="lazy" decoding="async" width="917" height="617" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19082502/Trade-Alert.jpg" alt="" class="wp-image-13076" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19082502/Trade-Alert.jpg 917w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19082502/Trade-Alert-300x202.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19082502/Trade-Alert-768x517.jpg 768w" sizes="(max-width: 917px) 100vw, 917px" /></a></figure>
Our LEAPS expire in January, 2027.
If you want a heads up when we place our next trade, you can subscribe to the Portfolio Armor trading Substack below.&nbsp;
If you&#8217;d like to stay in touch
You can scan for optimal hedges for individual securities, find our current top ten names, and&nbsp;create hedged portfolios&nbsp;on&nbsp;<a href="https://portfolioarmor.com/">our website</a>.&nbsp;You can also follow Portfolio Armor on X&nbsp;<a href="https://twitter.com/portfolioarmor">here</a>, or become a free subscriber to our trading Substack using the link below (we&#8217;re using that for our occasional emails now).
<figure class="wp-block-image aligncenter size-full"><a href="https://portfolioarmor.substack.com/"><img loading="lazy" decoding="async" width="581" height="372" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19082648/Widget-5.jpg" alt="" class="wp-image-13077" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19082648/Widget-5.jpg 581w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19082648/Widget-5-300x192.jpg 300w" sizes="(max-width: 581px) 100vw, 581px" /></a></figure>

Biotech

Equities

Options

Opinion

DXCM

PODD

SANA

The End Of The Diabetes Industry? This Small Cap Could Upend The Business Models of Pharma Giants

Maxim Group analyst Anthony Vendetti maintains Sensus Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRTS#NASDAQ">SRTS</a>) with a Buy and lowers the price target from $14 to $10.

SRTS

Maxim Group Maintains Buy on Sensus Healthcare, Lowers Price Target to $10

Shares of SoundHound AI Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>) fell 7.8% to $10.32 on Monday, potentially due to profit-taking following a robust 37% rally over the past month. The pullback comes after the company <a href="https://www.benzinga.com/news/earnings/25/05/45302790/soundhound-ai-stock-slides-on-mixed-q1-results-reaffirms-fy25-outlook">reported</a> first-quarter earnings on May 8 that showed strong growth but fell short on revenue expectations.
What To Know: The voice AI company posted first-quarter revenue of $29.13 million, missing <a href="https://www.benzinga.com/25/05/45316296/soundhounds-q1-fueled-by-polaris-strategic-acquisitions-and-record-pipeline-despite-missing-revenue-expectations">analyst estimates</a> of $30.38 million. However, it reported a narrower-than-expected adjusted loss of six cents per share, beating forecasts by three cents. 
Revenue surged 151% year-over-year, bolstered by strategic acquisitions and strong demand from the automotive and restaurant sectors.
Despite a sequential dip in gross margin and an adjusted EBITDA loss of $22.2 million, SoundHound reaffirmed its 2025 revenue guidance of $157 million to $177 million. The company ended the quarter with $246 million in cash and no debt.
Analysts <a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45356352/soundhound-ai-expansion-in-autos-and-dining-plus-q4-profit-target-fuels-bullish-analyst-view">noted</a> expanding customer diversification and a growing pipeline as positives. H.C. Wainwright meanwhile lowered its price target to $18 but maintained a Buy rating, citing long-term potential driven by the company&#8217;s proprietary AI platform and expanding market footprint.
Read Also: <a href="https://www.benzinga.com/markets/25/05/45473520/3-stocks-that-will-profit-from-trumps-drug-price-cut">3 Stocks That Will Profit From Trump&#8217;s Drug Price Cut</a>
<h2 class="wp-block-heading">How To Buy SOUN Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in SoundHound AI&#8217;s case, it is in the Information Technology sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, SOUN has a 52-week high of $24.98 and a 52-week low of $3.82.

Comments

Relmada Therapeutics

ニュース

最新ニュース Relmada Therapeutics (NASDAQ:RLMD) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル